Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.38 |
| ▸ | PTPRA | P18433 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28005090 | 0.87 | GRIA2 (0.46) | SCN9AGRIA2KDM4EPTPRA | |
| SCHEMBL15541594 | 0.87 | GRIA2 (0.46) | SCN9AGRIA2KDM4EPTPRA | |
| SCHEMBL6763196 | 0.81 | GRIA2 (0.40) | GRIA2KDM4EPTPRA | |
| SCHEMBL15540819 | 0.81 | PPARG (0.47) | GRIA2 | |
| SCHEMBL3781272 | 0.80 | SCN9A (0.47) | SCN9AGPR34EGLN2 | |
| SCHEMBL3775956 | 0.77 | GRIA2 (0.48) | GRIA2PTPRA | |
| SCHEMBL3775959 | 0.77 | GRIA2 (0.48) | GRIA2PTPRA | |
| SCHEMBL20982744 | 0.76 | MAPT (0.49) | KDM4EPGR | |
| SCHEMBL31176940 | 0.76 | MAPT (0.49) | KDM4EPGR | |
| SCHEMBL6578552 | 0.75 | MERTK (0.53) | GRIA2KDM4EPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443092-B1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | SCN9A 1463/4885GRIA2 46/4885KDM4E 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.